The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets
Introduction: Chronic kidney disease is characterized by an irreversible and gradually progressive process. Recent research has highlighted the role of metabolites derived from the intestinal microbiota as important factors in the progression of this disease. Consequently, numerous studies have foc...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Kazimierz Wielki University
2025-01-01
|
Series: | Journal of Education, Health and Sport |
Subjects: | |
Online Access: | https://apcz.umk.pl/JEHS/article/view/57110 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841545944765562880 |
---|---|
author | Daria Dąbkowska Agnieszka Mioskowska Joanna Szydziak Aleksandra Hrapkowicz Kinga Janowska Olga Szeidl Dominika Rehan Julia Wołoszczak |
author_facet | Daria Dąbkowska Agnieszka Mioskowska Joanna Szydziak Aleksandra Hrapkowicz Kinga Janowska Olga Szeidl Dominika Rehan Julia Wołoszczak |
author_sort | Daria Dąbkowska |
collection | DOAJ |
description |
Introduction: Chronic kidney disease is characterized by an irreversible and gradually progressive process. Recent research has highlighted the role of metabolites derived from the intestinal microbiota as important factors in the progression of this disease. Consequently, numerous studies have focused on the impact of the microbiota, its diagnostic potential, and its therapeutic applications.
Aim of the study: This study highlights the role of specific gut microbiota in chronic kidney disease and its potential applications in diagnosis and therapy.
Material and methods: An English-language literature review was conducted, analyzing studies from the PubMed database up to December 2024 regarding the correlation between specific gut microbiota and chronic kidney disease. The review was performed using the PubMed database, with 57 works used.
Conclusion: Chronic kidney disease is characterized by a slow, progressive, and irreversible decline in kidney function. Recent studies have highlighted the significant role of metabolites produced by the intestinal microbiota in the progression of this disease. Consequently, extensive research has been conducted on the impact of these metabolites for diagnostic purposes as well as their potential therapeutic applications. These metabolites can aid in both diagnosing the condition and predicting its progression. Emerging therapies that manipulate the microbiota—through approaches such as dietary changes, probiotics, modulation of bacterial metabolites, fecal microbiota transplantation, or the use of genetically modified bacteria—have shown promising results. However, further research is essential to fully develop and refine these therapeutic strategies.
|
format | Article |
id | doaj-art-e16ed56766b64164a7291c0834a61658 |
institution | Kabale University |
issn | 2391-8306 |
language | English |
publishDate | 2025-01-01 |
publisher | Kazimierz Wielki University |
record_format | Article |
series | Journal of Education, Health and Sport |
spelling | doaj-art-e16ed56766b64164a7291c0834a616582025-01-11T08:16:42ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062025-01-017710.12775/JEHS.2025.77.57110The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic TargetsDaria Dąbkowska0https://orcid.org/0009-0009-0101-0378Agnieszka Mioskowska1https://orcid.org/0009-0009-9731-4738Joanna Szydziak2https://orcid.org/0009-0004-3303-6402Aleksandra Hrapkowicz3https://orcid.org/0009-0009-8368-8536Kinga Janowska4https://orcid.org/0009-0007-1661-3388Olga Szeidl5https://orcid.org/0009-0006-0691-2571Dominika Rehan6https://orcid.org/0009-0000-9796-599XJulia Wołoszczak7https://orcid.org/0009-0003-3241-649XInfant Jesus Clinical Hospital in Warsaw Williama Heerleina Lindleya 4, 02-005 WarsawUniversity Clinical Center in Gdańsk ul. Dębinki 7, 80-952 Gdańsk, PolandJ. Gromkowski Provincial Specialist Hospital Koszarowa 5, 51-149 Wrocław, PolandT. Marciniak Lower Silesia Specialist Hospital–Centre for Medical Emergency, A.E. Fieldorfa 2, 54-049 Wrocław, PolandJ. Gromkowski Provincial Specialist Hospital Koszarowa 5, 51-149 Wrocław, PolandDr. Antoni Jurasz University Hospital No. 1 Marii Skłodowskiej-Curie 9, 85-094, BydgoszczLower Silesian Center for Oncology, Pulmonology and Hematology Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland4 Military Clinical Hospital with Polyclinic SP ZOZ ul. Rudolfa Weigla 5, 50-981 Wrocław, Poland Introduction: Chronic kidney disease is characterized by an irreversible and gradually progressive process. Recent research has highlighted the role of metabolites derived from the intestinal microbiota as important factors in the progression of this disease. Consequently, numerous studies have focused on the impact of the microbiota, its diagnostic potential, and its therapeutic applications. Aim of the study: This study highlights the role of specific gut microbiota in chronic kidney disease and its potential applications in diagnosis and therapy. Material and methods: An English-language literature review was conducted, analyzing studies from the PubMed database up to December 2024 regarding the correlation between specific gut microbiota and chronic kidney disease. The review was performed using the PubMed database, with 57 works used. Conclusion: Chronic kidney disease is characterized by a slow, progressive, and irreversible decline in kidney function. Recent studies have highlighted the significant role of metabolites produced by the intestinal microbiota in the progression of this disease. Consequently, extensive research has been conducted on the impact of these metabolites for diagnostic purposes as well as their potential therapeutic applications. These metabolites can aid in both diagnosing the condition and predicting its progression. Emerging therapies that manipulate the microbiota—through approaches such as dietary changes, probiotics, modulation of bacterial metabolites, fecal microbiota transplantation, or the use of genetically modified bacteria—have shown promising results. However, further research is essential to fully develop and refine these therapeutic strategies. https://apcz.umk.pl/JEHS/article/view/57110chronic kidney diseasegut microbiotamodulation of bacterial metabolitesfecal microbiota transplantation |
spellingShingle | Daria Dąbkowska Agnieszka Mioskowska Joanna Szydziak Aleksandra Hrapkowicz Kinga Janowska Olga Szeidl Dominika Rehan Julia Wołoszczak The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets Journal of Education, Health and Sport chronic kidney disease gut microbiota modulation of bacterial metabolites fecal microbiota transplantation |
title | The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets |
title_full | The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets |
title_fullStr | The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets |
title_full_unstemmed | The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets |
title_short | The Impact of Specific Gut Microbiota Metabolites on Chronic Kidney Disease Progression: Novel Diagnostic Biomarkers and Therapeutic Targets |
title_sort | impact of specific gut microbiota metabolites on chronic kidney disease progression novel diagnostic biomarkers and therapeutic targets |
topic | chronic kidney disease gut microbiota modulation of bacterial metabolites fecal microbiota transplantation |
url | https://apcz.umk.pl/JEHS/article/view/57110 |
work_keys_str_mv | AT dariadabkowska theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT agnieszkamioskowska theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT joannaszydziak theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT aleksandrahrapkowicz theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT kingajanowska theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT olgaszeidl theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT dominikarehan theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT juliawołoszczak theimpactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT dariadabkowska impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT agnieszkamioskowska impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT joannaszydziak impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT aleksandrahrapkowicz impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT kingajanowska impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT olgaszeidl impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT dominikarehan impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets AT juliawołoszczak impactofspecificgutmicrobiotametabolitesonchronickidneydiseaseprogressionnoveldiagnosticbiomarkersandtherapeutictargets |